Full Text of HB2028 97th General Assembly
HB2028 97TH GENERAL ASSEMBLY |
| | 97TH GENERAL ASSEMBLY
State of Illinois
2011 and 2012 HB2028 Introduced , by Rep. Dan Reitz SYNOPSIS AS INTRODUCED: |
| 225 ILCS 85/3 | | 225 ILCS 85/5.7 | | 225 ILCS 85/9.8 new | | 225 ILCS 85/23 | from Ch. 111, par. 4143 |
|
Amends the Pharmacy Practice Act. Defines "pharmacist clinician", "prescriptive authority" and "appropriately trained". Provides that a pharmacist clinician shall have on file at his or her place of practice written guidelines and protocols authorizing prescriptive authority. Provides that the guidelines and protocols authorizing prescriptive authority shall include a statement (i) identifying the practitioner authorized to prescribe and the pharmacist clinician who is a party to the guidelines or protocol, (ii) of the types of decisions a pharmacist clinician is authorize to make, (iii) of the activities the pharmacist clinician is to follow in the course of exercising prescriptive authority, and (iv) that describes appropriate mechanisms for reporting to the practitioner monitoring activities and results. Provides that claims of professional superiority in filling prescriptions or in any manner implying professional superiority that may reduce the public confidence in the ability, character, or integrity of other pharmacies or pharmacists are unlawful. Provides restrictions in advertising. Makes other changes. Effective immediately.
|
| |
| | A BILL FOR |
|
| | | HB2028 | | LRB097 06516 CEL 46600 b |
|
| 1 | | AN ACT concerning regulation.
| 2 | | Be it enacted by the People of the State of Illinois,
| 3 | | represented in the General Assembly:
| 4 | | Section 5. The Pharmacy Practice Act is amended by changing | 5 | | Sections 3, 5.7, and 23 and by adding Sections 9.8 and 26.5 as | 6 | | follows:
| 7 | | (225 ILCS 85/3)
| 8 | | (Section scheduled to be repealed on January 1, 2018)
| 9 | | Sec. 3. Definitions. For the purpose of this Act, except | 10 | | where otherwise
limited therein:
| 11 | | (a) "Pharmacy" or "drugstore" means and includes every | 12 | | store, shop,
pharmacy department, or other place where | 13 | | pharmacist
care is
provided
by a pharmacist (1) where drugs, | 14 | | medicines, or poisons are
dispensed, sold or
offered for sale | 15 | | at retail, or displayed for sale at retail; or
(2)
where
| 16 | | prescriptions of physicians, dentists, advanced practice | 17 | | nurses, physician assistants, veterinarians, podiatrists, or
| 18 | | optometrists, within the limits of their
licenses, are
| 19 | | compounded, filled, or dispensed; or (3) which has upon it or
| 20 | | displayed within
it, or affixed to or used in connection with | 21 | | it, a sign bearing the word or
words "Pharmacist", "Druggist", | 22 | | "Pharmacy", "Pharmaceutical
Care", "Apothecary", "Drugstore",
| 23 | | "Medicine Store", "Prescriptions", "Drugs", "Dispensary", |
| | | HB2028 | - 2 - | LRB097 06516 CEL 46600 b |
|
| 1 | | "Medicines", or any word
or words of similar or like import, | 2 | | either in the English language
or any other language; or (4) | 3 | | where the characteristic prescription
sign (Rx) or similar | 4 | | design is exhibited; or (5) any store, or
shop,
or other place | 5 | | with respect to which any of the above words, objects,
signs or | 6 | | designs are used in any advertisement.
| 7 | | (b) "Drugs" means and includes (l) articles recognized
in | 8 | | the official United States Pharmacopoeia/National Formulary | 9 | | (USP/NF),
or any supplement thereto and being intended for and | 10 | | having for their
main use the diagnosis, cure, mitigation, | 11 | | treatment or prevention of
disease in man or other animals, as | 12 | | approved by the United States Food and
Drug Administration, but | 13 | | does not include devices or their components, parts,
or | 14 | | accessories; and (2) all other articles intended
for and having | 15 | | for their main use the diagnosis, cure, mitigation,
treatment | 16 | | or prevention of disease in man or other animals, as approved
| 17 | | by the United States Food and Drug Administration, but does not | 18 | | include
devices or their components, parts, or accessories; and | 19 | | (3) articles
(other than food) having for their main use and | 20 | | intended
to affect the structure or any function of the body of | 21 | | man or other
animals; and (4) articles having for their main | 22 | | use and intended
for use as a component or any articles | 23 | | specified in clause (l), (2)
or (3); but does not include | 24 | | devices or their components, parts or
accessories.
| 25 | | (c) "Medicines" means and includes all drugs intended for
| 26 | | human or veterinary use approved by the United States Food and |
| | | HB2028 | - 3 - | LRB097 06516 CEL 46600 b |
|
| 1 | | Drug
Administration.
| 2 | | (d) "Practice of pharmacy" means (1) the interpretation and | 3 | | the provision of assistance in the monitoring, evaluation, and | 4 | | implementation of prescription drug orders; (2) the dispensing | 5 | | of prescription drug orders; (3) participation in drug and | 6 | | device selection; (4) drug administration limited to the | 7 | | administration of oral, topical, injectable, and inhalation as | 8 | | follows: in the context of patient education on the proper use | 9 | | or delivery of medications; vaccination of patients 14 years of | 10 | | age and older pursuant to a valid prescription or standing | 11 | | order, by a physician licensed to practice medicine in all its | 12 | | branches, upon completion of appropriate training, including | 13 | | how to address contraindications and adverse reactions set | 14 | | forth by rule, with notification to the patient's physician and | 15 | | appropriate record retention, or pursuant to hospital pharmacy | 16 | | and therapeutics committee policies and procedures; (5) drug | 17 | | regimen review; (6) drug or drug-related research; (7) the | 18 | | provision of patient counseling; (8) the practice of | 19 | | telepharmacy; (9) the provision of those acts or services | 20 | | necessary to provide pharmacist care; (10) medication therapy | 21 | | management; (11) the provision of therapeutic diabetic shoes | 22 | | and inserts by an appropriately trained pharmacist licensed in | 23 | | the State or an appropriately trained pharmacy's registered | 24 | | employee acting under the direct supervision of the pharmacist; | 25 | | and (12) (11) the responsibility for compounding and labeling | 26 | | of drugs and devices (except labeling by a manufacturer, |
| | | HB2028 | - 4 - | LRB097 06516 CEL 46600 b |
|
| 1 | | repackager, or distributor of non-prescription drugs and | 2 | | commercially packaged legend drugs and devices), proper and | 3 | | safe storage of drugs and devices, and maintenance of required | 4 | | records. A pharmacist who performs any of the acts defined as | 5 | | the practice of pharmacy in this State must be actively | 6 | | licensed as a pharmacist under this Act.
| 7 | | (e) "Prescription" means and includes any written, oral, | 8 | | facsimile, or
electronically transmitted order for drugs
or | 9 | | medical devices, issued by a physician licensed to practice | 10 | | medicine in
all its branches, dentist, veterinarian, or | 11 | | podiatrist, or
optometrist, within the
limits of their | 12 | | licenses, by a physician assistant in accordance with
| 13 | | subsection (f) of Section 4, or by an advanced practice nurse | 14 | | in
accordance with subsection (g) of Section 4, containing the
| 15 | | following: (l) name
of the patient; (2) date when prescription | 16 | | was issued; (3) name
and strength of drug or description of the | 17 | | medical device prescribed;
and (4) quantity; (5) directions for | 18 | | use; (6) prescriber's name,
address,
and signature; and (7) DEA | 19 | | number where required, for controlled
substances.
The | 20 | | prescription may, but is not required to, list the illness, | 21 | | disease, or condition for which the drug or device is being | 22 | | prescribed. DEA numbers shall not be required on inpatient drug | 23 | | orders.
| 24 | | (f) "Person" means and includes a natural person, | 25 | | copartnership,
association, corporation, government entity, or | 26 | | any other legal
entity.
|
| | | HB2028 | - 5 - | LRB097 06516 CEL 46600 b |
|
| 1 | | (g) "Department" means the Department of Financial and
| 2 | | Professional Regulation.
| 3 | | (h) "Board of Pharmacy" or "Board" means the State Board
of | 4 | | Pharmacy of the Department of Financial and Professional | 5 | | Regulation.
| 6 | | (i) "Secretary"
means the Secretary
of Financial and | 7 | | Professional Regulation.
| 8 | | (j) "Drug product selection" means the interchange for a
| 9 | | prescribed pharmaceutical product in accordance with Section | 10 | | 25 of
this Act and Section 3.14 of the Illinois Food, Drug and | 11 | | Cosmetic Act.
| 12 | | (k) "Inpatient drug order" means an order issued by an | 13 | | authorized
prescriber for a resident or patient of a facility | 14 | | licensed under the
Nursing Home Care Act, the MR/DD Community | 15 | | Care Act, or the Hospital Licensing Act, or "An Act in relation | 16 | | to
the founding and operation of the University of Illinois | 17 | | Hospital and the
conduct of University of Illinois health care | 18 | | programs", approved July 3, 1931,
as amended, or a facility | 19 | | which is operated by the Department of Human
Services (as | 20 | | successor to the Department of Mental Health
and Developmental | 21 | | Disabilities) or the Department of Corrections.
| 22 | | (k-5) "Pharmacist" means an individual health care | 23 | | professional and
provider currently licensed by this State to | 24 | | engage in the practice of
pharmacy.
| 25 | | (l) "Pharmacist in charge" means the licensed pharmacist | 26 | | whose name appears
on a pharmacy license and who is responsible |
| | | HB2028 | - 6 - | LRB097 06516 CEL 46600 b |
|
| 1 | | for all aspects of the
operation related to the practice of | 2 | | pharmacy.
| 3 | | (m) "Dispense" or "dispensing" means the interpretation, | 4 | | evaluation, and implementation of a prescription drug order, | 5 | | including the preparation and delivery of a drug or device to a | 6 | | patient or patient's agent in a suitable container | 7 | | appropriately labeled for subsequent administration to or use | 8 | | by a patient in accordance with applicable State and federal | 9 | | laws and regulations.
"Dispense" or "dispensing" does not mean | 10 | | the physical delivery to a patient or a
patient's | 11 | | representative in a home or institution by a designee of a | 12 | | pharmacist
or by common carrier. "Dispense" or "dispensing" | 13 | | also does not mean the physical delivery
of a drug or medical | 14 | | device to a patient or patient's representative by a
| 15 | | pharmacist's designee within a pharmacy or drugstore while the | 16 | | pharmacist is
on duty and the pharmacy is open.
| 17 | | (n) "Nonresident pharmacy"
means a pharmacy that is located | 18 | | in a state, commonwealth, or territory
of the United States, | 19 | | other than Illinois, that delivers, dispenses, or
distributes, | 20 | | through the United States Postal Service, commercially | 21 | | acceptable parcel delivery service, or other common
carrier, to | 22 | | Illinois residents, any substance which requires a | 23 | | prescription.
| 24 | | (o) "Compounding" means the preparation and mixing of | 25 | | components, excluding flavorings, (1) as the result of a | 26 | | prescriber's prescription drug order or initiative based on the |
| | | HB2028 | - 7 - | LRB097 06516 CEL 46600 b |
|
| 1 | | prescriber-patient-pharmacist relationship in the course of | 2 | | professional practice or (2) for the purpose of, or incident | 3 | | to, research, teaching, or chemical analysis and not for sale | 4 | | or dispensing. "Compounding" includes the preparation of drugs | 5 | | or devices in anticipation of receiving prescription drug | 6 | | orders based on routine, regularly observed dispensing | 7 | | patterns. Commercially available products may be compounded | 8 | | for dispensing to individual patients only if all of the | 9 | | following conditions are met: (i) the commercial product is not | 10 | | reasonably available from normal distribution channels in a | 11 | | timely manner to meet the patient's needs and (ii) the | 12 | | prescribing practitioner has requested that the drug be | 13 | | compounded.
| 14 | | (p) (Blank).
| 15 | | (q) (Blank).
| 16 | | (r) "Patient counseling" means the communication between a | 17 | | pharmacist or a student pharmacist under the supervision of a | 18 | | pharmacist and a patient or the patient's representative about | 19 | | the patient's medication or device for the purpose of | 20 | | optimizing proper use of prescription medications or devices. | 21 | | "Patient counseling" may include without limitation (1) | 22 | | obtaining a medication history; (2) acquiring a patient's | 23 | | allergies and health conditions; (3) facilitation of the | 24 | | patient's understanding of the intended use of the medication; | 25 | | (4) proper directions for use; (5) significant potential | 26 | | adverse events; (6) potential food-drug interactions; and (7) |
| | | HB2028 | - 8 - | LRB097 06516 CEL 46600 b |
|
| 1 | | the need to be compliant with the medication therapy. A | 2 | | pharmacy technician may only participate in the following | 3 | | aspects of patient counseling under the supervision of a | 4 | | pharmacist: (1) obtaining medication history; (2) providing | 5 | | the offer for counseling by a pharmacist or student pharmacist; | 6 | | and (3) acquiring a patient's allergies and health conditions.
| 7 | | (s) "Patient profiles" or "patient drug therapy record" | 8 | | means the
obtaining, recording, and maintenance of patient | 9 | | prescription
information, including prescriptions for | 10 | | controlled substances, and
personal information.
| 11 | | (t) (Blank).
| 12 | | (u) "Medical device" means an instrument, apparatus, | 13 | | implement, machine,
contrivance, implant, in vitro reagent, or | 14 | | other similar or related article,
including any component part | 15 | | or accessory, required under federal law to
bear the label | 16 | | "Caution: Federal law requires dispensing by or on the order
of | 17 | | a physician". A seller of goods and services who, only for the | 18 | | purpose of
retail sales, compounds, sells, rents, or leases | 19 | | medical devices shall not,
by reasons thereof, be required to | 20 | | be a licensed pharmacy.
| 21 | | (v) "Unique identifier" means an electronic signature, | 22 | | handwritten
signature or initials, thumb print, or other | 23 | | acceptable biometric
or electronic identification process as | 24 | | approved by the Department.
| 25 | | (w) "Current usual and customary retail price" means the | 26 | | price that a pharmacy charges to a non-third-party payor.
|
| | | HB2028 | - 9 - | LRB097 06516 CEL 46600 b |
|
| 1 | | (x) "Automated pharmacy system" means a mechanical system | 2 | | located within the confines of the pharmacy or remote location | 3 | | that performs operations or activities, other than compounding | 4 | | or administration, relative to storage, packaging, dispensing, | 5 | | or distribution of medication, and which collects, controls, | 6 | | and maintains all transaction information. | 7 | | (y) "Drug regimen review" means and includes the evaluation | 8 | | of prescription drug orders and patient records for (1)
known | 9 | | allergies; (2) drug or potential therapy contraindications;
| 10 | | (3) reasonable dose, duration of use, and route of | 11 | | administration, taking into consideration factors such as age, | 12 | | gender, and contraindications; (4) reasonable directions for | 13 | | use; (5) potential or actual adverse drug reactions; (6) | 14 | | drug-drug interactions; (7) drug-food interactions; (8) | 15 | | drug-disease contraindications; (9) therapeutic duplication; | 16 | | (10) patient laboratory values when authorized and available; | 17 | | (11) proper utilization (including over or under utilization) | 18 | | and optimum therapeutic outcomes; and (12) abuse and misuse.
| 19 | | (z) "Electronic transmission prescription" means any | 20 | | prescription order for which a facsimile or electronic image of | 21 | | the order is electronically transmitted from a licensed | 22 | | prescriber to a pharmacy. "Electronic transmission | 23 | | prescription" includes both data and image prescriptions.
| 24 | | (aa) "Medication therapy management services" means a | 25 | | distinct service or group of services offered by licensed | 26 | | pharmacists, physicians licensed to practice medicine in all |
| | | HB2028 | - 10 - | LRB097 06516 CEL 46600 b |
|
| 1 | | its branches, advanced practice nurses authorized in a written | 2 | | agreement with a physician licensed to practice medicine in all | 3 | | its branches, or physician assistants authorized in guidelines | 4 | | by a supervising physician that optimize therapeutic outcomes | 5 | | for individual patients through improved medication use. In a | 6 | | retail or other non-hospital pharmacy, medication therapy | 7 | | management services shall consist of the evaluation of | 8 | | prescription drug orders and patient medication records to | 9 | | resolve conflicts with the following: | 10 | | (1) known allergies; | 11 | | (2) drug or potential therapy contraindications; | 12 | | (3) reasonable dose, duration of use, and route of | 13 | | administration, taking into consideration factors such as | 14 | | age, gender, and contraindications; | 15 | | (4) reasonable directions for use; | 16 | | (5) potential or actual adverse drug reactions; | 17 | | (6) drug-drug interactions; | 18 | | (7) drug-food interactions; | 19 | | (8) drug-disease contraindications; | 20 | | (9) identification of therapeutic duplication; | 21 | | (10) patient laboratory values when authorized and | 22 | | available; | 23 | | (11) proper utilization (including over or under | 24 | | utilization) and optimum therapeutic outcomes; and | 25 | | (12) drug abuse and misuse. | 26 | | "Medication therapy management services" includes the |
| | | HB2028 | - 11 - | LRB097 06516 CEL 46600 b |
|
| 1 | | following: | 2 | | (1) documenting the services delivered and | 3 | | communicating the information provided to patients' | 4 | | prescribers within an appropriate time frame, not to exceed | 5 | | 48 hours; | 6 | | (2) providing patient counseling designed to enhance a | 7 | | patient's understanding and the appropriate use of his or | 8 | | her medications; and | 9 | | (3) providing information, support services, and | 10 | | resources designed to enhance a patient's adherence with | 11 | | his or her prescribed therapeutic regimens.
| 12 | | "Medication therapy management services" may also include | 13 | | patient care functions authorized by a physician licensed to | 14 | | practice medicine in all its branches for his or her identified | 15 | | patient or groups of patients under specified conditions or | 16 | | limitations in a standing order from the physician. | 17 | | "Medication therapy management services" in a licensed | 18 | | hospital may also include the following: | 19 | | (1) reviewing assessments of the patient's health | 20 | | status; and | 21 | | (2) following protocols of a hospital pharmacy and | 22 | | therapeutics committee with respect to the fulfillment of | 23 | | medication orders.
| 24 | | (bb) "Pharmacist care" means the provision by a pharmacist | 25 | | of medication therapy management services, with or without the | 26 | | dispensing of drugs or devices, intended to achieve outcomes |
| | | HB2028 | - 12 - | LRB097 06516 CEL 46600 b |
|
| 1 | | that improve patient health, quality of life, and comfort and | 2 | | enhance patient safety.
| 3 | | (cc) "Protected health information" means individually | 4 | | identifiable health information that, except as otherwise | 5 | | provided, is:
| 6 | | (1) transmitted by electronic media; | 7 | | (2) maintained in any medium set forth in the | 8 | | definition of "electronic media" in the federal Health | 9 | | Insurance Portability and Accountability Act; or | 10 | | (3) transmitted or maintained in any other form or | 11 | | medium. | 12 | | "Protected health information" does not include individually | 13 | | identifiable health information found in: | 14 | | (1) education records covered by the federal Family | 15 | | Educational Right and Privacy Act; or | 16 | | (2) employment records held by a licensee in its role | 17 | | as an employer. | 18 | | (dd) "Standing order" means a specific order for a patient | 19 | | or group of patients issued by a physician licensed to practice | 20 | | medicine in all its branches in Illinois. | 21 | | (ee) "Address of record" means the address recorded by the | 22 | | Department in the applicant's or licensee's application file or | 23 | | license file, as maintained by the Department's licensure | 24 | | maintenance unit. | 25 | | (ff) "Home pharmacy" means the location of a pharmacy's | 26 | | primary operations.
|
| | | HB2028 | - 13 - | LRB097 06516 CEL 46600 b |
|
| 1 | | (gg) "Pharmacist clinician" means a pharmacist who is | 2 | | recognized as a licensed health care provider with additional | 3 | | training who exercises prescriptive authority in accordance | 4 | | with authority granted under a properly executed standing order | 5 | | as set forth in this Act. | 6 | | (hh) "Prescriptive authority" means the authority to | 7 | | initiate, manage, or modify a drug or drug therapies as | 8 | | specified in a standing order with a valid licensed prescriber. | 9 | | (ii) "Appropriately trained" means the satisfactory | 10 | | completion of one of the following: (i) a course of study that | 11 | | covers fitting and patient management of therapeutic diabetic | 12 | | shoes and inserts that is approved by the National Commission | 13 | | of Orthotic and Prosthetic Education (N.C.O.P.E.), (ii) an | 14 | | appropriate manufacturer's training course consisting of | 15 | | fitting of therapeutic shoes with assessment to be completed to | 16 | | prove success, or (iii) a course of study that covers fitting | 17 | | and patient management of therapeutic diabetic shoes and | 18 | | inserts that are approved by a nationally recognized orthotic | 19 | | and prosthetic certification or accreditation organization | 20 | | that has its certification or accreditation programs | 21 | | recognized by the National Commission for Certifying Agencies. | 22 | | (jj) "Therapeutic diabetic shoes and inserts" means any of | 23 | | the Healthcare Common Procedure Coding System (HCPCS) codes | 24 | | A5500, A5510, A5512, or A5513. | 25 | | (Source: P.A. 95-689, eff. 10-29-07; 96-339, eff. 7-1-10; | 26 | | 96-673, eff. 1-1-10; 96-1000, eff. 7-2-10; 96-1353, eff. |
| | | HB2028 | - 14 - | LRB097 06516 CEL 46600 b |
|
| 1 | | 7-28-10.)
| 2 | | (225 ILCS 85/5.7)
| 3 | | (Section scheduled to be repealed on January 1, 2018)
| 4 | | Sec. 5.7. Advertising services. | 5 | | (a) A licensee shall include in every advertisement for | 6 | | services regulated under
this
Act his or her title as it
| 7 | | appears on the license or the initials authorized under this | 8 | | Act.
| 9 | | (b) The claiming of professional superiority in the filling | 10 | | of prescriptions or in any manner implying the professional | 11 | | superiority that may reduce the public confidence in the | 12 | | ability, character, or integrity of another pharmacy or | 13 | | pharmacist is unlawful. It shall be unlawful for a pharmacist | 14 | | or pharmacy to do any of the following: | 15 | | (1) use testimonials or claims of superior quality of | 16 | | product or care to entice the public; | 17 | | (2) advertise in any way that misleads or presents | 18 | | information that is intended to mislead the public; | 19 | | (3) advertise or offer gifts as an inducement or offer | 20 | | prescription medications without costs or without co-pays; | 21 | | and | 22 | | (4) offer or provide prescription pads with | 23 | | promotional information such as directions to specific | 24 | | pharmacies or disclose or direct patients by recommending | 25 | | pricing information. |
| | | HB2028 | - 15 - | LRB097 06516 CEL 46600 b |
|
| 1 | | (Source: P.A. 91-310, eff. 1-1-00 .)
| 2 | | (225 ILCS 85/9.8 new) | 3 | | Sec. 9.8. Pharmacist clinician prescriptive authority. | 4 | | (a) A pharmacist clinician planning to exercise | 5 | | prescriptive authority in his or her practice shall have on | 6 | | file at his or her place of practice written guidelines or | 7 | | protocol. The guidelines or protocol shall authorize a | 8 | | pharmacist clinician to exercise prescriptive authority and | 9 | | shall be established and approved by a practitioner in | 10 | | accordance with regulations adopted by the Board. The duly | 11 | | licensed practitioner who is a party to the standing order | 12 | | shall be in active practice and the prescriptive authority that | 13 | | he or she grants to a pharmacist clinician shall be within the | 14 | | scope of the practitioner's current practice. | 15 | | (b) The guidelines or protocol required by subsection (a) | 16 | | shall include: | 17 | | (1) a statement identifying the practitioner | 18 | | authorized to prescribe and the pharmacist clinician who is | 19 | | a party to the guidelines or protocol; | 20 | | (2) a statement of the types of prescriptive authority | 21 | | decisions that the pharmacist clinician is authorized to | 22 | | make that may include: | 23 | | (A) a statement of the types of diseases, dangerous | 24 | | drugs, or dangerous drug categories involved and the | 25 | | type of prescriptive authority authorized in each |
| | | HB2028 | - 16 - | LRB097 06516 CEL 46600 b |
|
| 1 | | case; and | 2 | | (B) a general statement of the procedures, | 3 | | decision criteria, or plan the pharmacist clinician is | 4 | | to follow when exercising prescriptive authority. | 5 | | (3) a statement of the activities the pharmacist | 6 | | clinician is to follow in the course of exercising | 7 | | prescriptive authority, including documentation of | 8 | | decisions made and a plan for communication or feedback to | 9 | | the authorizing practitioner concerning specific decisions | 10 | | made; documentation may occur on the prescriptive record, | 11 | | patient profile, patient medical chart, or in a separate | 12 | | log book; and | 13 | | (4) a statement that describes appropriate mechanisms | 14 | | for reporting to the practitioner monitoring activities | 15 | | and results. | 16 | | (c) The written guidelines or protocol shall be reviewed | 17 | | and shall be revised every 2 years if necessary. | 18 | | (d) A pharmacist clinician planning to exercise | 19 | | prescriptive authority in his or her practice shall be | 20 | | authorized to monitor dangerous drug therapy.
| 21 | | (225 ILCS 85/23) (from Ch. 111, par. 4143)
| 22 | | (Section scheduled to be repealed on January 1, 2018)
| 23 | | Sec. 23.
It is unlawful for a pharmacist or pharmacy to pay | 24 | | or
promise to pay to any person who owns, operates, manages or | 25 | | is an employee
of a hospital, nursing home or other health care |
| | | HB2028 | - 17 - | LRB097 06516 CEL 46600 b |
|
| 1 | | facility or to any
person authorized by law to prescribe drugs | 2 | | or to any entity in which
a person authorized by law to | 3 | | prescribe drugs holds an interest, any
rebate, refund, | 4 | | discount, commission or other valuable consideration
for, on | 5 | | account of, or based upon income received or resulting from
the | 6 | | sale or furnishing by any such pharmacy of drugs or devices, | 7 | | prescriptions
or any other service to patients of the above | 8 | | specified persons, organizations
or facilities.
| 9 | | This shall not be deemed to include rent or other | 10 | | remunerations paid
to an individual, partnership, or | 11 | | corporation by a pharmacist or pharmacy
for the lease, rental, | 12 | | or use of space, owned or controlled, by the
individual, | 13 | | partnership or corporation.
| 14 | | It is unlawful for any licensed pharmacist, pharmacy, or | 15 | | registered licensee to engage in the offering, use, or | 16 | | distribution of any premiums, coupons, rebates, inducements, | 17 | | or any kind of economic incentive to transfer prescriptions. | 18 | | (Source: P.A. 85-796 .)
| 19 | | Section 99. Effective date. This Act takes effect upon | 20 | | becoming law.
|
|